Therapeutic Cancer Vaccination With a Peptide Derived From the Calreticulin Exon 9 Mutations Induces Strong Cellular Immune Responses in Patients With CALR-Mutant Chronic Myeloproliferative Neoplasms

BACKGROUND: The calreticulin (CALR) exon 9 mutations that are identified in 20% of patients with Philadelphia chromosome negative chronic myeloproliferative neoplasms (MPN) generate immunogenic antigens. Thus, therapeutic cancer vaccination against mutant CALR could be a new treatment modality in CA...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Front Oncol
Asıl Yazarlar: Handlos Grauslund, Jacob, Holmström, Morten Orebo, Jørgensen, Nicolai Grønne, Klausen, Uffe, Weis-Banke, Stine Emilie, El Fassi, Daniel, Schöllkopf, Claudia, Clausen, Mette Borg, Gjerdrum, Lise Mette Rahbek, Breinholt, Marie Fredslund, Kjeldsen, Julie Westerlin, Hansen, Morten, Koschmieder, Steffen, Chatain, Nicolas, Novotny, Guy Wayne, Petersen, Jesper, Kjær, Lasse, Skov, Vibe, Met, Özcan, Svane, Inge Marie, Hasselbalch, Hans Carl, Andersen, Mads Hald
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Frontiers Media S.A. 2021
Konular:
Oncology
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7952976/
https://ncbi.nlm.nih.gov/pubmed/33718228
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.637420
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller